Short lung transplant donor telomere length is associated with decreased CLAD-free survival. by Faust, Hilary E et al.
UCSF
UC San Francisco Previously Published Works
Title
Short lung transplant donor telomere length is associated with decreased CLAD-free 
survival.
Permalink
https://escholarship.org/uc/item/8c97d154
Journal
Thorax, 72(11)
ISSN
0040-6376
Authors
Faust, Hilary E
Golden, Jeffrey A
Rajalingam, Raja
et al.
Publication Date
2017-11-01
DOI
10.1136/thoraxjnl-2016-209897
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Short Lung Transplant Donor Telomere Length is 
Associated with Decreased CLAD-Free Survival 
 
Hilary E Faust1,2, Jeff A Golden2, Raja Rajalingam2, Angelia S Wang2, Gary Green2, Steven R 
Hays2, Jasleen Kukreja2, Jonathan P Singer2, Paul J Wolters2*, John R Greenland2, 3* 
 
1Pulmonary, Allergy and Critical Care Division, Perelman School of Medicine, Philadelphia, 
Pennsylvania, USA 2University of California, San Francisco, and 3San Francisco VA Medical 
Center, San Francisco, California, USA 
 
 
* Correspondence and requests for reprints should be addressed to John R. Greenland MD, 
PhD, San Francisco VA Medical Center, 4150 Clement St, San Francisco CA 94121. E-mail 
john.greenland@ucsf.edu or Paul J Wolters MD University of California, San Francisco, Box 
0111, San Francisco, CA 94143-0111. E-mail: paul.wolters@ucsf.edu 
 
ABSTRACT:  
Telomere length (TL) decreases with cellular aging and biologic stressors. As advanced donor 
and recipient age are risk factors for chronic lung allograft dysfunction (CLAD), we hypothesized 
that decreased age-adjusted donor TL would predict earlier onset of CLAD. Shorter donor TL was 
associated with increased risk of CLAD or death (HR 1.26 per 1-kb TL decrease, 95%CI 1.03-
1.54), particularly for young donors. Recipient TL was associated with cytopenias but not CLAD. 
Shorter TL was also seen in airway epithelium for subjects progressing to CLAD (P = 0.02). 
Allograft telomere length may contribute to CLAD pathogenesis and facilitate risk stratification. 
 
INTRODUCTION: 
Chronic lung allograft dysfunction (CLAD) 
reflects progressive fibrosis and constitutes the 
most common cause of death after the first 
year following transplant1. However, time to 
development of CLAD varies substantially 
across lung transplant recipients.  While donor 
and recipient age are risk factors for decreased 
CLAD-free survival, they do not fully capture 
the extent of molecular aging.2 
 
Telomeres are nucleoprotein caps on the 
terminal region of chromosomes that provide 
protection from chromosomal shortening 
during cell replication. TLs vary inversely with 
age but are widely distributed within cells and 
cell populations. TL shortening past a critical 
length triggers cellular senescence. 
Accelerated telomere attrition is associated 
with increased cell turnover and stress, while 
inherited or sporadic mutations in telomerase-
associated genes cause syndromes mimicking 
early aging.3 
 
Short allograft TL has been associated with 
delayed graft function and chronic allograft 
dysfunction following renal transplantation4 
and poor graft survival following stem-cell 
transplant for aplastic anemia.5 Case series of 
recipients with known telomerase mutations 
following lung transplantation suggest an 
increased risk of leukopenia but did not 
evaluate CLAD.6 A small retrospective lung 
transplantation cohort study found no 
association between donor or recipient 
peripheral blood TL and survival.7 
 
Telomere dysfunction in lung disease has been 
increasingly appreciated, as telomere-related 
mutations are implicated in familial pulmonary 
fibrosis and chronic obstructive pulmonary 
disease.8 Experimentally, telomere dysfunction 
induced by selective deletion of the shelterin 
complex proteins in alveolar type II cells results 
in epithelial cell failure, remodeling, and 
fibrosis.9  
 
These observations motivated the hypothesis 
that shortened donor peripheral blood 
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telomeres would identify lung allografts at 
increased risk for early CLAD or death 
following transplantation. 
 
METHODS: 
See supplement for detailed methods. Briefly, 
lung allograft recipients at UCSF were included 
if they provided informed consent, donor and 
recipient DNA samples were available, and had 
at least 18 months of follow up data 
(Supplemental Table 1). We measured TL by 
quantitative PCR on DNA isolated from 
peripheral blood mononuclear cells 
(PBMC) or spleen. For the sub-cohort 
described in Supplemental Table 4, TL in 
endobronchial biopsies collected within 
90 days following transplant was 
measured by quantitative Fluorescence 
in Situ Hybridization (Q-FISH).  
 
RESULTS: 
Demographic features of the 175 
included subjects are summarized in 
Supplemental Table 2. Mean donor TL 
exceeded that of recipients by 1.0 kb 
(95% CI 0.8-1.2, P <0.001) and by 0.5 kb 
(95% CI 0.2-0.7, P <0.001) after adjusting 
for age. Forty-five percent of recipients 
developed CLAD with a median time to 
CLAD of 3.8 years and 28% of subjects 
died. Median follow up time was 4.9 years 
(IQR 4.0 years). TL was inversely 
correlated to age for the entire cohort 
(Figure 1A). 
 
Shorter donor TL was associated with an 
increased risk of CLAD or death with an 
adjusted HR of 1.25 per 1-kb decrease in 
TL (95% CI 1.03-1.52, 88 events, P = 
0.02, Figures 1B-C). Recipient TL and 
donor age were not associated with 
CLAD-free survival (Table 1). Interaction 
modeling suggested that short donor 
telomeres are most hazardous in younger 
donors (P = 0.01). In a competing risks 
analysis adjusted for subject 
characteristics, decreasing donor TL was 
associated with both CLAD censored on 
death (subdistribution HR 1.25, 95% CI 
1.00-1.56, 72 events, P = 0.045) and death 
alone (subdistribution HR 1.43, 95% CI 1.06-
1.93, 40 events, P = 0.02). 
 
An increased odds ratio of mild (OR 2.5, 95% 
CI 1.1-5.5) and severe leukopenia (OR 4.8, 
95% CI 1.8-13.0) was found amongst 
recipients in the lowest 20th percentile of PBMC 
TL (Supplemental Table 5). 
 
Endobronchial TL was measured in subjects 
with extremes of time to CLAD to determine the  
Table 1: Cox proportional hazards models for CLAD-
free survival as a function of donor and recipient 
telomere length. 
Multivariable risk of CLAD or death model† ‡	 	 	 Hazard ratio 95% CI P-value 
Telomere length (per 1 kb decrease)		 Donor 1.25 1.03 - 1.52 0.02 	 Recipient 1.02 0.87 - 1.2 0.79 
Age (per decade)		 Donor 1.03 0.86 - 1.22 0.76 	 Recipient 1.06 0.8 - 1.41 0.67 
Multivariable risk of CLAD or death 
interaction model† 
 
	 	 Hazard ratio 95% CI P-value 
Telomere length (per 1 kb decrease)		 Donor 2.39 1.4 - 4.07 0.001 
Age (per decade)		 Donor 0.29 0.11 - 0.79 0.02 
Donor Age * Donor Telomere length 	 Interaction 0.83 0.71 - 0.96 0.01 
Donor-age stratified, multivariable-adjusted risk of 
CLAD or death models†		 	 Hazard ratio 95% CI P-value	
Donor telomere length (per 1 kb decrease) 	 Donor Age <30 1.65 1.18 - 2.31 0.004 	 Donor Age ≥30 1 0.79 - 1.27 0.97 
†Includes donor and recipient telomere length, age, 
diagnosis group, lung allocation score, donor gender, 
recipient gender, non-Hispanic white donor, non-
Hispanic white recipient, transplant type, and donor 
"ever smoker" status. 
‡Univariable and multivariable models including all 
covariates are included as Supplemental Table 3. 
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association with allograft TL. The populations 
are described in Supplemental Table 4. 
Endobronchial TL was significantly greater in 
the >8 year CLAD-free group, relative to those 
that developed CLAD at a median of 2.9 years 
(P = 0.02, Figure 1F). 
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DISCUSSION: 
In summary, short donor PBMC TL was 
associated with worse CLAD-free survival, 
independent of donor age, in univariable and 
multivariable models, while recipient TL was 
associated with increased incidence of post-
transplant leukopenia. TL was also shorter in 
airway epithelial cells from lung allografts that 
went on to develop CLAD, suggesting that 
decreased TL within the lung may directly 
contribute to the development of CLAD. 
 
Genetic predisposition or environmental insults 
affecting the lung may contribute to short 
telomeres. Telomere shortening beyond what 
is expected with aging might signify systemic or 
inherited telomere dysfunction, which may 
explain the observed interaction with donor 
age. Cell turnover that is either homeostatic or 
in response to injury is impaired in the context 
of critically short telomeres. Allografts with 
short telomeres may have a higher frequency 
of senescent cells and thus be at increased risk 
for the airway-centric or parenchymal lung 
fibrosis that are pathologic correlates of 
CLAD.1 Lung allografts may be particularly 
susceptible to telomere attrition because of 
repeated environmental insults or high rates of 
cell turnover relative to other solid organs.10  
Recipient PBMC TL was associated with 
clinically significant leukopenia, consistent with 
previous reports of increased leukopenia in 
lung allograft recipients with telomerase 
mutations.6 Short PBMC TL may reflect a 
larger population of senescent bone marrow 
cells unable to increase leukocyte production, 
particularly under the influence of 
immunosuppressive medications. Assessment 
of recipient TL has the potential to guide post-
transplantation immunosuppressive and 
antiviral dosing. 
 
Strengths of this study include the large sample 
size relative to other investigations of TL in lung 
transplantation,7 length of follow up, uniform 
assessment of TL with quality controls, and 
confirmation with measurement of TL in airway 
tissue. The study is from a single center, 
limiting differences in clinical practice; 
however, external validation would strengthen 
the generalizability of the findings. In particular, 
relative to ISHLT registry reports, this cohort 
included more recipients transplanted for 
pulmonary fibrosis.2 Also, we did not evaluate 
TL relevance for subjects with <18 months 
follow up. 
 
Our findings, if replicated, may assist with 
improved stratification of donor risk, and 
facilitate the use of lungs from donors of 
advanced age if TL is found to be adequate. 
Telomerase activation may be of interest in 
allografts with short TL.3 
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Supplemental Data 
 
Supplemental Table 1: Subject inclusion and exclusion table 
 
683 Lung transplants at UCSF between 4/15/2000 and 3/2/2015 
 82 Survived < 18 months 
 285 Not approached 
316 Approached for study 
 6 Refused 
310 Consented 
 114 Missing donor DNA sample 
 81 Missing recipient DNA sample 
 31 <18mo follow up data available 
182 DNA samples evaluated 
 7 Donor or recipient DNA sample degraded 
175 Subjects included 
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Supplemental Table 1 (cont): Subject characteristics 
  
  DNA missing DNA available P-value 
Subjects 135 175  
Age, mean (sd) 
 Recipient 54 (11) 54 (13) 0.95 
 Donor 32 (14) 32 (14) 0.67 
Diagnosis group, N (%) 
 A 18 (13%) 43 (25%) 0.03 
 B 6 (4%) 11 (6%)  
 C 12 (9%) 21 (12%)  
 D 99 (73%) 100 (57%)  
Female, N (%) 
 Recipient 60 (44%) 83 (47%) 0.61 
 Donor 64 (47%) 62 (35%) 0.07 
Transplant type, N (%) 
 Double lung 124 (92%) 157 (90%) 0.80 
 Single lung 9 (7%) 15 (9%)  
 Heart-lung 2 (1%) 3 (2%)  
White Non-Hispanic, N (%) 
 Recipient 98 (73%) 136 (78%) 0.36 
 Donor 63 (47%) 82 (47%) 0.83 
Lung allocation score, 
mean (sd) 59 (22) 54 (21) 0.07 
Donor ever smoker, N (%) 7 (5%) 18 (10%) 0.24 
CLAD-free survival, median 
years (95% CI) 6.1 (4.5-7.3) 5.5 (4.5-7.0) 0.62 
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Supplemental Table 2: Subject characteristics stratified by quintile of donor telomere length.  
 
  Total 
Quintile of donor telomere length 
P-value 
  <20% 20-40% 40-60% 60-80% >80% 
Subjects 175 35 35 35 35 35  
Maximum telomere length, 
kilobases 11.16 6.0 6.6 6.9 7.5 11.16  
Age, mean (SD)              
 Recipient 54 (12) 56 (12) 56 (10) 54 (14) 54 (13) 51 (14) 0.05 
 Donor 33 (14) 36 (16) 35 (14) 31 (12) 32 (12) 31 (14) 0.04 
Diagnosis group, N (%)              
 Group A (COPD) 43 (25%) 8 (23%) 8 (23%) 9 (26%) 8 (23%) 10 (29%) 0.12 
 Group B (PAH) 11 (6%) 3 (9%) 0 (0%) 1 (3%) 1 (3%) 6 (17%)  
 Group C (CF) 21 (12%) 4 (11%) 2 (6%) 7 (20%) 3 (9%) 5 (14%)  
 Group D (PF) 100 (57%) 20 (57%) 25 (71%) 18 (51%) 23 (66%) 14 (40%)  
Female, N (%)              
 Recipient 83 (47%) 15 (43%) 16 (46%) 16 (46%) 15 (43%) 21 (60%) 0.24 
 Donor 62 (35%) 10 (29%) 12 (34%) 12 (34%) 12 (34%) 16 (46%) 0.18 
Transplant type, N (%)              
 Double lung 157 (90%) 31 (89%) 33 (94%) 32 (91%) 32 (91%) 29 (83%) 0.83 
 Single lung 15 (9%) 3 (9%) 2 (6%) 2 (6%) 3 (9%) 5 (14%)  
 Heart-lung 3 (2%) 1 (3%) 0 (0%) 1 (3%) 0 (0%) 1 (3%)  
White Non-Hispanic, N (%)              
 Recipient 136 (78%) 28 (80%) 27 (77%) 26 (74%) 27 (77%) 28 (80%) 1.00 
 Donor 82 (47%) 18 (51%) 15 (43%) 14 (40%) 15 (43%) 20 (57%) 0.59 
Lung allocation score, 
mean (SD) 53 (21) 55 (21) 52 (21) 53 (21) 55 (21) 51 (21) 0.41 
Donor ever smoker, N (%) 17 (10%) 0 (0%) 2 (6%) 1 (3%) 7 (20%) 7 (20%) 0.01 
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Supplemental Table 3: Univariable and multivariable CLAD-free survival Cox proportional hazards models. 
 
  Univariable  Multivariable 
  Hazard ratio 95% CI P-value  Hazard ratio 95% CI P-value 
Telomere length (per 1kb decrease)     
 Recipient 1.02 0.88 - 1.20 0.76  1.02 0.87 - 1.20 0.79 
 Donor 1.25 1.04 - 1.50 0.02  1.25 1.03 - 1.52 0.02 
Age (decade)            
 Recipient 1.22 1.02 - 1.47 0.03  1.06 0.80 - 1.41 0.67 
 Donor 1.05 0.9 - 1.22 0.55  1.03 0.86 - 1.22 0.76 
Diagnosis group            
 Group A (COPD) 1.28 0.79 - 2.06 0.74  1.34 0.74 - 2.43 0.34 
 Group B (PAH) 0.74 0.26 - 2.06 0.74  0.62 0.16 - 2.39 0.48 
 Group C (CF) 0.81 0.42 - 1.59 0.74  0.82 0.33 - 2.07 0.68 
 Group D (PF) 1    -      - 
Female            
 Recipient 1 0.66 - 1.52 1.00  1.26 0.78 - 2.02 0.35 
 Donor 0.57 0.36 - 0.91 0.02  0.55 0.32 - 0.95 0.03 
Transplant type            
 Double lung 1    -  1    - 
 Single lung 1.06 0.53 - 2.12 0.72  1.20 0.52 - 2.77 0.66 
 Heart-lung 2.08 0.51 - 8.53 0.72  2.53 0.49 - 13.0 0.27 
White Non-Hispanic            
 Recipient 1.23 0.74 - 2.05 0.43  1.24 0.66 - 2.32 0.51 
 Donor 0.88 0.58 - 1.35 0.57  0.87 0.55 - 1.36 0.54 
Lung allocation score 1 0.99 - 1.01 1.00  1.00 0.99 - 1.02 0.76 
Donor ever smoker 0.92 0.49 - 1.73 0.79  1.01 0.48 - 2.10 0.99 
 
Supplemental Table 4: Telomere-FISH nested sub-cohort subject characteristics 
 
  Total CLAD-free CLAD P-value 
Subjects 175 6 9  
CLAD-free years, median 3.5 > 8 2.9  
Endobronchial biopsy days 
post-transplant, median (IQR)   30 (34) 37 (10) 0.32 
Telomere length, kb median (IQR)       
 Recipient 5.9 (1.4) 5.4 (2.0) 6.2 (1.0) 0.18 
 Donor 6.7 (1.1) 9.2 (1.0) 5.7 (2.7) 0.05 
Age, mean (SD)        
 Recipient 54 (12) 50 (11) 61 (9) 0.06 
 Donor 33 (14) 28 (14) 37 (18) 0.34 
Diagnosis group, N (%)        
 Group A (COPD) 43 (25%) 5 (83%) 5 (56%) 0.10 
 Group B (PAH) 11 (6%) 0 (0%) 0 (0%)  
 Group C (CF) 21 (12%) 1 (17%) 0 (0%)  
 Group D (PF) 100 (57%) 0 (0%) 4 (44%)  
Female, N (%)        
 Recipient 83 (47%) 2 (33%) 4 (44%) 1.00 
 Donor 62 (35%) 3 (50%) 2 (22%) 0.58 
Transplant type, N (%)        
 Double lung 157 (90%) 5 (83%) 7 (78%) 1.00 
 Single lung 15 (9%) 1 (17%) 2 (22%)  
 Heart-lung 3 (2%) 0 (0%) 0 (0%)  
White Non-Hispanic, N (%)        
 Recipient 136 (78%) 4 (67%) 8 (89%) 0.69 
 Donor 82 (47%) 5 (83%) 6 (67%) 0.91 
Lung allocation score, mean 53  33  46  NA 
Donor ever smoker, N (%) 17 (10%) 1 (17%) 1 (11%) 1.00 
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Supplemental Table 5: Incidence of cytopenia by recipient telomere length 
 
Recipient telomere length 
 
 Shortest quintile (N=33) 
Remaining 
quintiles (N=120) P-value 
Leukopenia, N (%)      
 Mild (WBC <4,000/μL) 17 (52%) 34 (28%) 0.02 
 Severe (WBC <2,500/μL) 10 (30%) 10 (8%) 0.002 
Anemia, N (%)      
 Hb < 7 g/dL 6 (18%) 14 (12%) 0.49 
Thrombocytopenia, N (%)      
 Mild (Plt <100,000/μL) 14 (42%) 38 (32%) 0.34 
 Severe (Plt <50,000/μL) 5 (15%) 10 (8%) 0.40 
Any cytopenia, N (%)      
 Mild 21 (64%) 65 (54%) 0.44 
 Severe 14 (42%) 25 (21%) 0.02 
 
Incidence of hematopoetic dysfunction in the first 90 days post-transplant for recipients above and below 
the lower 20th percentile of recipient PBMC telomere length (4.98 kb). 
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Supplemental Methods 
 
Subject samples and clinical data: This study was approved under University of California, San Francisco 
(UCSF) Institutional Review Board protocols 13-10738 and 10-00721. Recipients of lung transplantation at 
UCSF were included if they provided informed consent, donor and recipient DNA samples were available, 
and had at least 18 months of follow up data. Donor DNA was isolated from peripheral blood mononuclear 
cells (PBMC) or spleen, in order of preference. Quality of DNA samples was determined by gel electrophoresis 
and samples excluded if there was evidence of DNA degradation. DNA degradation was detected in 2.0% of 
donor samples and 2.1% of recipient samples. 
Serial spirometry was collected on subjects dating from the time of transplant per clinical protocols. Time to 
CLAD was determined from date of FEV1 or FVC decline by 20% of the post-transplant baseline as previously 
described.1 2 Data on white blood cell count, hemoglobin, and platelet counts were collected from electronic 
medical records. Survival data was determined from UCSF electronic medical records and from the United 
Network for Organ Sharing (UNOS) database. Telomere shortening may even be accelerated in lung tissue 
relative to shortening of PBMC telomeres.3 Therefore, in a nested case-control study, telomere length was 
also measured on formalin-fixed plasma-embedded endobronchial biopsies that were collected within the first 
90 days following transplant. Subjects were selected based on extremes of time to development of CLAD, 
with the 6 CLAD-free patients having the longest CLAD-free intervals of our subjects and the CLAD patients 
having the shortest CLAD-free intervals. 
 
Peripheral blood telomere length measurements: We measured telomere lengths in a blinded manner, 
using quantitative PCR (qPRC) on donor and recipient PBMC or splenic DNA. DNA was visualized on agarose 
gel to determine quality, and degraded DNA samples were excluded from the analysis. We performed uniplex 
qPCR in triplicate with the 36B4 gene as a reference housekeeping gene. Assays were repeated until the 
sample standard deviation was less than 0.5. Relative telomere lengths were determined by subtracting 
telomere and reference median cycle threshold (CT) values. To facilitate comparison with other studies, 
absolute telomere lengths were interpolated from study sample delta CT values using linear regression with 
delta CT values for reference samples. Telomere length for these reference samples was determined by 
mean terminal restriction fragment length.4  
 
Telomere Q-FISH assay: In a nested case-control group of 6 subjects who developed CLAD and 12 subjects 
who did not, telomere lengths were measured on paraffin-embedded sections of endobronchial biopsy tissue 
by Quantitative Fluorescence in Situ Hybridization (Q-FISH). It should be noted that this small sample size 
could possibly limit power to identify associations. Briefly, after deparaffinization, tissues were suspended in 
10mM sodium citrate buffer, pH 6.5, heated in a microwave, then incubated for 15 min in 0.01M HCL 
containing 1% pepsin (Thermo Fisher Scientific, South San Francisco, CA). The tissues were washed then 
treated with 10mg/ml RNase solution (Qiagen, Hilden, Germany). After washing, the tissues were incubated 
with 0.3 µg/ml of the TelC-Cy3 Peptide Nucleic Acid (PNA) probe (F1002, Panagene, Daejeon, Korea) 
suspended in formamide buffer (70% formamide, 10 mmol/L Tris, pH 7.5), heated to 78ºC for 10 min then 
incubated overnight at 20ºC. The tissues were then washed sequentially with formamide buffer then PBS 
containing 0.1% Tween, blocked with 3% BSA (Sigma, St. Louis, MO), 10% donkey serum, and incubated 
overnight at 4ºC with rabbit anti-human E cadherin antibody (#3195S, Cell Signaling Technology, Danvers, 
MA). Tissues were washed with PBS containing 0.1% Tween and incubated with Alexa Fluor 488 goat anti-
rabbit IgG secondary antibody (#A11008, Thermo Fisher Scientific) at 20ºC for 1 h, washed, and mounted 
using prolong gold anti-fade mounting medium with DAPI (Thermo Fisher Scientific). Images were acquired 
using a Zeiss Axio Imager 2 microscope (Zeiss, Oberkochen, Germany) and telomere signal intensity 
quantified using MetaMorph imaging analysis software (Molecular Devices, Sunnyvale, CA). Telo-FISH 
staining and quantification were performed in a blinded manner. 
 
Analysis: Differences in subject characteristics across donor telomere length quintile number were 
determined by continuous or logistic generalized linear modeling or chi-square test, as appropriate. Telomere 
lengths in donors and recipients as a function of age were assessed by linear regression. CLAD-free survival 
per one-kilobase decrease in donor and recipient telomere length was determined by Cox proportional 
hazards modeling.5 All 175 available samples were analyzed, for which a post-hoc power calculation identified 
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a 50%, 80% and 95% power to detect a hazard ratio for CLAD or death of 1.2, 1.3, and 1.4, respectively, per 
1 kb change in telomere length.6 Quintile extremes of telomere length were compared to the remainder of the 
population using Kaplan-Meier analysis. In multivariable Cox models, we adjusted for donor and recipient 
age, gender, and race; diagnosis group; LAS score; donor smoking; and transplant procedure. Missing values 
were imputed using 10-fold multiple imputations by chained equations for donor smoking (N=2), donor age 
(N=2), donor gender (N=1), donor ethnicity (N=1), and lung allocation score (N=21).7 Imputation using median 
value did not substantially alter the results. The Cox proportional hazard ratio as a function of time was 
computed using penalized smoothing splines.8 We also performed competing risks analysis evaluating 
mortality as a competing risk for CLAD. We assessed the proportionality assumption of these Cox models 
through inspection of the Schoenfeld residual plot and chi-squared test of correlation between Schoenfeld 
residuals versus CLAD-free survival time.  
 
Logistic regression was used to evaluate for an association between recipient telomere length in the lowest 
quintile and post-transplant cytopenias. Leukopenia was defined by a white blood cell count per microliter of 
4,000 and 2,500, which is our clinical threshold to decrease or hold, respectively, mycophenolate mofetil 
and/or valgancyclovir. Tissue-specific telomere lengths between CLAD and no CLAD groups were compared 
by Mann Whitney test.  
 
Statistics were calculated in R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).  
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